Free Metanephrines

If you've had unexplained episodes of racing heart, pounding headaches, sweating, or blood pressure that swings wildly for no clear reason, this is the test that can tell you whether a rare hormone-producing tumor is the hidden cause. It's also the first test ordered when an unexpected mass turns up on an adrenal gland or when a family history points to inherited tumor risk.

Free metanephrines are considered the most accurate blood test available for finding these tumors, with the ability to pick them up when standard labs and blood pressure readings look deceptively normal. A single well-collected result can either rule the condition out with high confidence or flag a problem that needs immediate follow-up.

What This Test Actually Measures

Free metanephrines are the small chemical leftovers (metanephrine, normetanephrine, and sometimes methoxytyramine) produced when your body breaks down adrenaline, noradrenaline, and dopamine. These breakdown products, known as O-methylated catecholamine metabolites, circulate in the blood in a "free" form that directly reflects ongoing hormone production rather than brief stress spikes.

The main reason to measure them is to detect pheochromocytoma and paraganglioma (PPGL), rare tumors that grow in the adrenal glands or related nerve tissue and pump out excess stress hormones. These tumors continuously metabolize catecholamines inside the tumor itself, which leaks a steady stream of metanephrines into the blood. That's what makes this test so sensitive: you're catching a constant signal, not waiting for a moment when the tumor happens to fire off hormones.

Why These Tumors Matter

Pheochromocytomas and paragangliomas are uncommon, but when they exist and go undiagnosed, they can cause sudden severe hypertension, heart attacks, strokes, and life-threatening surgical complications. Tumors that produce mostly adrenaline drive up metanephrine. Tumors producing noradrenaline drive up normetanephrine. Tumors producing dopamine (often more aggressive) raise methoxytyramine, which is also linked to higher risk of tumor spread and shorter survival.

Catching these tumors early matters because surgical removal is usually curative, and resection normalizes the catecholamine excess and its downstream effects on blood pressure, metabolism, and heart function.

How the Test Performs

Plasma free metanephrines are the most accurate biochemical test for PPGL available. The numbers below come from studies and meta-analyses of patients being evaluated for these tumors.

Sources: Lenders et al., JAMA 2002; Chen et al., meta-analysis 2017; Ahn et al., 2021.

What this means for you: a normal, well-collected result is strong evidence that you do not have a hormone-producing tumor. A high result does not automatically mean you do. Because the condition is rare, many elevated readings are false positives driven by how the blood was drawn or by medications and stress. Abnormal results always need careful follow-up, not panic.

Heart and Blood Pressure Risk

Marked elevations of normetanephrine or metanephrine strongly suggest a catecholamine-producing tumor that can cause dangerous blood pressure surges, arrhythmias, and acute cardiovascular events. Tumor resection typically reverses these effects. Observational data link higher urinary metanephrine levels to cardiovascular complications and metabolic disturbances, supporting close monitoring of anyone with sustained elevations.

Tumor Aggressiveness and Prognosis

In 639 patients with PPGL, higher plasma methoxytyramine was independently linked to shorter disease-specific survival, and elevated methoxytyramine patterns often signal dopaminergic tumors with more aggressive behavior, including a higher chance of metastatic spread. The pattern of which metanephrines are elevated also predicts where the tumor is likely to be located and which genetic mutation may underlie it.

Inherited Tumor Syndromes

People with known mutations (NF1, RET, VHL, SDHx) or a family history of PPGL benefit most from periodic testing. In one pediatric cohort, plasma free metanephrines using age-specific reference ranges caught tumors with 100% sensitivity and flagged disease about a year earlier than adult cutoffs. If you have a family history of these tumors or adrenal masses, this is information worth collecting proactively.

Reference Ranges

Reference intervals for free metanephrines vary by assay (LC-MS/MS vs immunoassay), laboratory, sampling posture, and specimen type (plasma vs urine). The ranges below reflect the most commonly used diagnostic framework in the PPGL literature, not universal cutpoints. These are meant as orientation. Your lab will report its own reference interval and units, and you should compare your results within the same lab over time.

Sources: Lenders et al., Endocrine Society Clinical Practice Guideline 2014; Grouzmann et al., 2010.

When Results Can Be Misleading

A single plasma free metanephrine reading is highly sensitive but can be thrown off by sampling conditions and medical context. A large study of over 3,000 patients identified specific factors that raise normetanephrine and drive false positives:

• Posture and setting: outpatient, seated blood draws produced about 41 to 44% higher normetanephrine and a 3 to 4 times higher false-positive rate compared with fully supine inpatient sampling
• Draw technique: direct venipuncture (as opposed to drawing from an indwelling cannula after 20 minutes of rest) increased metanephrine by about 17% and roughly doubled false-positive odds
• Cold exposure: cooler ambient temperature on the test day raised normetanephrine and nearly doubled false-positive odds through sympathetic nervous system activation
• Kidney impairment: in advanced chronic kidney disease and dialysis, plasma free metanephrine and normetanephrine often rise into the range seen with actual tumors, requiring kidney-specific reference intervals

Preanalytical factors, including drug interference from agents such as sulfasalazine and acetaminophen, can produce a "phantom pheochromocytoma" picture, where the lab looks abnormal but no tumor exists. If your first result is elevated, the single most useful next step is retesting under optimized conditions before pursuing imaging.

Tracking Your Trend

A single reading collected in imperfect conditions is a far weaker piece of evidence than a consistent pattern across multiple well-collected samples. If you've had a mildly elevated result, the right response is usually a repeat test under optimized conditions (supine, fasted, rested, drawn through a cannula after 20 minutes) rather than an immediate scan.

For people being monitored after tumor resection or those with inherited PPGL syndromes, regular surveillance matters because recurrence can be silent. Annual testing is reasonable for most at-risk individuals, with more frequent checks if new symptoms emerge or if the earlier reading was borderline. Tracking your own trend within the same lab gives you the clearest signal of whether something is genuinely changing.

What to Do If Your Result Is Abnormal

An elevated result is not a diagnosis. The decision pathway depends on how high the result is and the clinical context:

• Mild elevation, no symptoms, suboptimal collection: retest under standardized supine conditions with a cannula after 20 minutes of rest, fasting, and off interfering medications if possible
• Sustained mild elevation on optimized retest: a clonidine suppression test using plasma normetanephrine can distinguish true tumors from sympathetic false positives
• Marked elevation (more than 2 to 4 times the upper limit) or symptoms consistent with PPGL: cross-sectional imaging (CT first, MRI if radiation is a concern or metastatic disease is suspected) to locate the tumor
• Any confirmed PPGL: genetic testing is recommended, particularly for SDHx mutations, which affect surveillance strategy and inform relatives

An endocrinologist experienced with PPGL should be involved as soon as a confirmed elevation is established, both to guide imaging and to coordinate preoperative alpha-blockade if surgery is planned.